Potent incretin‐based therapy for obesity: A systematic review and meta‐analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety
Obesity Reviews · 2024-05 · 25 (5)
DOI: 10.1111/obr.13717 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Obesity Reviews, online erschienen am 11.03.2024. Verfasst von Alberte Laura Oest Müllertz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Obesity, Incretins, Waist Circumference. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Helsefonden, Novo Nordisk Foundation, Novo Nordisk Fonden.
Abstract (Originalsprache)
Potent incretin‐based therapy shows promise for the treatment of obesity along with reduced incidence of cardiovascular events in patients with preexisting cardiovascular disease and obesity. This study assessed the efficacy and safety of the incretin‐based obesity treatments, once‐weekly subcutaneous semaglutide 2.4 mg and tirzepatide 10 or 15 mg, in people with obesity without diabetes. Of the 744 records identified, seven randomized controlled trials ( n = 5140) were included. Five studies ( n = 3288) investigated semaglutide and two studies ( n = 1852) investigated tirzepatide. The treatment effect, shown as placebo‐subtracted difference, on body weight was −15.0% (95% CI, −17.8 to −12.2) with −12.9% (95% CI, −14.7 to −11.1) for semaglutide and −19.2% (95% CI, −22.2 to −16.2) for tirzepatide. The treatment effect on waist circumference was −11.4 cm (95% CI, −13.7 to −9.2) with −9.7 cm (95% CI, −10.8 to −8.5) for semaglutide and −14.6 cm (95% CI, −15.8 to −13.4) for tirzepatide. The adverse events related to semaglutide and tirzepatide were primarily of mild‐to‐moderate severity and mostly gastrointestinal, which was more frequent during the dose‐titration period and leveled off during the treatment period. This emphasizes that once‐weekly subcutaneous semaglutide 2.4 mg and tirzepatide 10 or 15 mg induce large reductions in body weight and waist circumference and are generally well‐tolerated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Alberte Laura Oest Müllertz, Rasmus Michael Sandsdal, Simon Birk Kjær Jensen, Signe Sørensen Torekov
Förderung
- Helsefonden
- Novo Nordisk Foundation
- Novo Nordisk Fonden
Zitieren
APA
Müllertz, A. L. O., Sandsdal, R. M., Jensen, S. B. K., & Torekov, S. S. (2024). Potent incretin‐based therapy for obesity: A systematic review and meta‐analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety. Obesity Reviews, 25(5). https://doi.org/10.1111/obr.13717
Vancouver
Müllertz ALO, Sandsdal RM, Jensen SBK, Torekov SS. Potent incretin‐based therapy for obesity: A systematic review and meta‐analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety. Obesity Reviews. 2024;25(5). doi:10.1111/obr.13717
BibTeX
@article{Mllertz2024,
author = {Müllertz, Alberte Laura Oest and Sandsdal, Rasmus Michael and Jensen, Simon Birk Kjær and Torekov, Signe Sørensen},
title = {Potent incretin‐based therapy for obesity: A systematic review and meta‐analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety},
journal = {Obesity Reviews},
year = {2024},
volume = {25},
number = {5},
doi = {10.1111/obr.13717}
}
EUVIMED